Beenken Andrew, Mohammadi Moosa
Department of Pharmacology, New York University School of Medicine, New York, New York 10016, USA.
Nat Rev Drug Discov. 2009 Mar;8(3):235-53. doi: 10.1038/nrd2792.
The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.
成纤维细胞生长因子（FGFs）家族调节着众多发育过程，包括脑模式形成、分支形态发生和肢体发育。目前已经在探索FGFs的多种促有丝分裂、细胞保护和血管生成治疗应用，并且最近发现具有内分泌作用的FGF19亚家族在胆汁酸、葡萄糖和磷酸盐稳态中发挥关键作用，这引发了人们对该家族药物潜力的新兴趣。本综述讨论了重组FGFs和小分子FGF受体激酶抑制剂在癌症和心血管疾病治疗中的传统应用，以及它们在代谢综合征和低磷血症性疾病治疗中的新潜力。
